Archive for March, 2008
GSK ends its antifolate drugs Lapdap and Dacart
0 Comments Published March 5th, 2008 in Treatment, Drug resistanceGlaxoSmithKline pulled Lapdap (chloroproguanil-dapsone) from the market and ended the development of Dacart (Lapdap+artesunate) after phase III trials of the drugs showed significant hemoglobin reductions in patients with glucose 6-phosphate dehydrogenase (G6PD) deficiency. Patient’s with G6PD deficiency have weaker red blood cell membranes which can rupture when exposed to oxidative stress caused by certain drugs […]
My goal for the blog is to achieve one post every day. Clearly, I’ve missed that mark, blogging while traveling is a trick which might take me some time to master. Until then, my apologies for any lapses in news and comments.
Last week Nature carried a commentary from Mark Grabowsky, malaria manager at the Global […]
Search
About
You are currently browsing the topnaman | Malaria blog weblog archives for March, 2008.
Longer entries are truncated. Click the headline of an entry to read it in its entirety.Latest
- Fighting malaria since the Skeeter beaters
- Mosquito syringes and more funded by the Gates foundations grand challenges
- Monitoring antimalarial drug resistance with molecular tools
- Survival - a new BBC global health series showcases malaria
- Launch of the Global Malaria Action Plan
- 2008 World malaria report released
- Resurrecting the past to create a new malaria vaccine
- Malaria elimination or eradication vs control - what is the big deal?
- The grand challenge of eradication - Gates Foundation is looking for new tools
- Malaria (and other communicable diseases) in Southeast Asia
Archives
Categories
- Advocacy (4)
- Climate (2)
- Communication (2)
- Delivery (2)
- Diagnosis (2)
- Drug resistance (6)
- Policy (9)
- Random (2)
- Research (3)
- Surveillance (5)
- Treatment (3)
- Vector control (2)
Categories
- Advocacy (4)
- Climate (2)
- Communication (2)
- Delivery (2)
- Diagnosis (2)
- Drug resistance (6)
- Policy (9)
- Random (2)
- Research (3)
- Surveillance (5)
- Treatment (3)
- Vector control (2)
